hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

Dated: November 29, 2006 Signature:

Docket No.: CELLTH 3.0-012

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: James A. Bianco

Group Art Unit: 1654 Application No.: 10/635,970

Filed: August 6, 2003 Examiner: R. R. Teller

For: COMBINATORIAL DRUG THERAPY USING

POLYMER-DRUG CONJUGATES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-captioned U.S. patent application. of each non-US patent reference and each non-patent literature reference is enclosed.

All of the U.S. provisional non-provisional and references, disclosed in paragraph 63, are cited herein in terms of their published counterparts (cite code AA, AN, AO, AP, AQ, AR, and AS).

Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: November 29, 2006

Respectfully submitted,

Shawn P. Foley

Registration No.: 33,071 LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP

600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

LD-458\ 712270_1.DOC

by certify that this paper (along with any paper referred to as being attached closed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: November 29, 2006 Signature:

Docket No.: CELLTH 3.0-012

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

James A. Bianco

Application No.: 10/635,970

Group Art Unit: 1654

Filed: August 6, 2003

Examiner: R. R. Teller

For: COMBINATORIAL DRUG THERAPY USING

POLYMER-DRUG CONJUGATES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REQUEST FOR CONSIDERATION OF INFORMATION UNDER 37 CFR § 1.97 (C)

Dear Sir:

It is respectfully requested that the references cited in the enclosed form be considered pursuant to 37 C.F.R. § 1.97(c). Please charge deposit account No. 12-1095 in the amount of \$180.00 pursuant to 37 C.F.R. § 1.17(p). In the event that any additional fee is due in connection with the present request, the same should be charged to our deposit account No. 12-1095.

Dated: November 29, 2006

Respectfully submitted,

Registration No.: 33,071 LERNER, DAVID, LITTENBERG,

KRUMHOLZ & MENTLIK, LLP 600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

LD-453\

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

2 Sheet 1 of

Complete if Known				
Application Number	10/635,970-Conf. #1243			
Filing Date	August 6, 2003			
First Named Inventor	James A. Bianco			
Art Unit	1654			
Examiner Name	R. R. Teller			
Attorney Docket Number	CELLTH 3.0-012			

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,977,163	11-02-1999	Li et al.	
	AB*	US-6,262,107	07-17-2001	Li et al.	
	AC*	US-5,470,510	11-28-1995	Willey et al.	
	AD*	US-4,554,101	11-19-1985	Норр	
	AE*	US-4,942,184	07-17-1990	Haugwitz et al.	
	AF*	US-5,731,316	03-24-1998	Cao et al.	
	AG*	US-6,441,025-A1	08-27-2002	Li et al.	
	AH*	US-6,150,398	11-21-2000	Vande Woude et al.	
	AI*	US-5,407,609	04-18-1995	Tice et al.	
	AJ*	US-5,753,234	05-19-1998	Lee et al.	
	AK*	US-5,496,804	03-05-1996	Reed et al.	
	AL*	US-5,641,803	06-24-1997	Carretta et al.	
	AM*	US-5,670,537	09-23-1997	Canetta et al.	
	AN*	US-6,515,017	02-04-2003	Li et al.	
	AO*	US-20030054977-A1	03-20-2003	Kumar et al.	
	AP*	US-20020077290-A1	06-20-2002	Bhatt et al.	
	AQ*	US-20020169125-A1	11-14-2002	Leung et al.	
	AR*	US-20030216289-A1	11-20-2003	Bhatt et al.	
	AS*	US-20030211973-A1	11-13-2003	Bhatt et al.	·

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite No.1	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Initials*		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY			T ⁶	
		EP-0 410 638-A	01-30-1991	Takeda Chemical Industries Ltd			
	ВВ	EP-0 058 481-A1	08-25-1982	Ici Plc			
- "	вс	WO-99/49901	10-07-1999	Pg Txl Company L P et al.			
	BD	WO-97/33552	09-18-1997	Wallace Tech Inc et al.			
	BE	WO-01/26693-A3	04-19-2001	Cell Therapeutics Inc et al.			
	BF	WO-01/70275-A2	09-27-2001	Cell Therapeutics Inc et al.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
Signature	Considered

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
	_			Application Number	10/635,970-Conf. #1243
11	NFORMATION	1 DI	SCLOSURE	Filing Date	August 6, 2003
S	STATEMENT BY APPLICANT			First Named Inventor	James A. Bianco
_				Art Unit	1654
	(Use as many sheets as necessary)			Examiner Name	R. R. Teller
Sheet	2	of	2	Attorney Docket Number	CELLTH 3.0-012

		NON PATENT LITERATURE DOCUMENTS .					
Examiner Initials	Cite No. ¹						
	CA	Cortes and Pazdur, Journal of Clinical Oncology 13:2643-2655 (1995)					
	СВ	Goldspiel, Ann. Pharmacotherapy 28:S23-26 (1994)					
	CC	Maeda and Matsumura, Critical Review in Therapeutic Drug Carrier Systems 6:193-1989					
	CD	T. Reynolds, J. Natl. Cancer Institute 87:1582 1995					
	CE	Kyte, J. & Doolittle, RF, J. Mol. Biol. May 5; 157(1) 105-32 1982					
	CF	Kohn, J. and Langer, R., Polymerization Reactions Involving the Side Chains of α -L-Amino Acids, J. Amer. Chem, Soc., 109, 917 (1987)					
	CG	Pulapura, S. and Kohn, J., Biomaterials Based on "Pseudo"-Poly(Amino Acids): A Study of Tyrosine Derived Polyiminocarbonates, J. Polymer Preprints, 31, 23 (1990)					
	СН	Hoffman, et al., Biol. Chem. 370:575-582, 1989					
	CI	Weismuller et al., Vaccine, 7;29-33, 1989					
	CJ	Weismuller et al., Int. J. Peptide Protein Res., 40:255-260, 1992					
	СК	Defoort et al. Proc. Natl. Acad. Sci. 89:3879-3883, 1992					
	CL	Toyokuni et al., J. Am. Chem. Soc., 116:395-396, 1994	Ī				
	СМ	Riechel, Chem. Commun., 2087-2088, 1997					
	CN	Kamitakahara, Angew. Chem. Int. Ed. 37:1524-1528, 1998					
	СО	Li, C., et al., Int. J. Radiat. Oncol. Biol. Phys. 48(4):1119-26 (2000)					
	CE1	Dullenkopf et al., Chem. Eur. J., 5:2432-2438, 1999					
			_				
			L				
			L				
			┢				
			H				
			ļ				
			H				
			T				
			Γ				
,			┢				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
Signature	Considered